Ameriprise
KROS icon

Ameriprise’s Keros Therapeutics KROS Stock Holding History

Ameriprise’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Sell
101,342
-1,137
-1% -$12.7K ﹤0.01% 3366
2026
Q1 		$1.13M Sell
102,479
-20,349
-17% -$314K ﹤0.01% 3238
2025
Q4 		$2.5M Buy
122,828
+2,395
+2% +$42K ﹤0.01% 2873
2025
Q3 		$1.91M Buy
120,433
+21,792
+22% +$322K ﹤0.01% 3029
2025
Q2 		$1.32M Buy
+98,641
New +$1.33M ﹤0.01% 3153

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Ameriprise's KROS Position: Q2 2026 in Review

Ameriprise reduced its Keros Therapeutics (KROS) stake by 1.1% in Q2 2026, selling an estimated $12.7K and leaving 101,342 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #3366.

Ameriprise first reported a position in KROS in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.5M in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Ameriprise held 101,342 shares of Keros Therapeutics worth $1.08M as of Q2 2026.
  • Ameriprise sold 1,137 Keros Therapeutics shares in Q2 2026, an estimated $12.7K.
  • Keros Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3366 holding.
  • Ameriprise first reported a position in Keros Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Ameriprise's Keros Therapeutics position peaked at $2.5M in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.